Rhythm Pharma director granted RSUs, stock options

RHYTHM PHARMACEUTICALS director Jean Christophe reported equity awards and an RSU conversion into common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

RHYTHM PHARMACEUTICALS director Jean Christophe reported equity awards and an RSU conversion into common stock. He received 2,324 restricted stock units, each representing one share of common stock, which fully vest upon the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service.

He also received stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, vesting on the same schedule and expiring on June 23, 2036. In addition, 4,712 previously granted restricted stock units were exercised and converted into 4,712 shares of common stock, leaving no remaining units from that grant. Following these transactions, he holds 11,712 shares of common stock directly.

Insider Trade Summary

4,712 shares exercised/converted

Exercise 4 txns

Insider JEAN CHRISTOPHE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,691	$0.00	$0.00
Grant/Award	Restricted Stock Units	2,324	$0.00	$0.00
Exercise	Restricted Stock Units	4,712	$0.00	$0.00
Exercise	Common Stock	4,712	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 3,691 contracts (Direct); Restricted Stock Units — 2,324 contracts (Direct); Common Stock — 11,712 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2. The restricted stock units are fully vested. The restricted stock units have no expiration date.
F3. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.
F4. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

Key Figures

RSU grant: 2,324 units Option grant size: 3,691 shares Option exercise price: $107.55 per share +4 more

7 metrics

RSU grant 2,324 units Restricted stock units granted to director, each for one common share

Option grant size 3,691 shares Stock options granted for common stock

Option exercise price $107.55 per share Conversion or exercise price of stock options

Option expiration June 23, 2036 Expiration date of stock options granted

RSUs converted 4,712 units Restricted stock units exercised into common stock

Common shares after 11,712 shares Common stock directly held after transactions

RSU grant vesting June 24, 2027 / pre-2027 meeting Earlier of date or day before 2027 annual meeting, subject to service

Key Terms

Restricted Stock Units, Stock Option (right to buy), derivative security, vest

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (right to buy) financial

"The options fully vest upon the earlier of June 24, 2027 or before the 2027 meeting"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vest financial

"The options fully vest upon the earlier of June 24, 2027 or the day"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Rhythm Pharmaceuticals (RYTM) director Jean Christophe receive?

Jean Christophe received 2,324 restricted stock units and stock options for 3,691 shares at $107.55 per share. Both awards vest by June 24, 2027 or the day before the 2027 annual meeting, subject to his continued service on the board.

How many Rhythm Pharmaceuticals (RYTM) shares does Jean Christophe hold after this Form 4?

After these transactions, Jean Christophe directly holds 11,712 shares of Rhythm Pharmaceuticals common stock. This reflects the conversion of 4,712 previously granted restricted stock units into common shares, with no open-market sales reported in this filing.

What happened to the 4,712 restricted stock units in Jean Christophe’s Rhythm (RYTM) filing?

4,712 restricted stock units were exercised and converted into 4,712 shares of Rhythm common stock. This transaction is coded as an exercise of a derivative security, leaving no remaining units from that specific RSU grant outstanding after the conversion.

When do Jean Christophe’s new Rhythm (RYTM) RSUs and options vest?

Both the 2,324 restricted stock units and the 3,691 stock options vest upon the earlier of June 24, 2027 or the day immediately prior to Rhythm’s 2027 annual shareholder meeting, provided Jean Christophe continues serving as a director through the applicable vesting date.

What is the exercise price and expiration date of Jean Christophe’s Rhythm (RYTM) options?

Jean Christophe’s newly granted stock options cover 3,691 shares of Rhythm common stock at an exercise price of $107.55 per share. These options expire on June 23, 2036, giving a long-dated window once vesting conditions tied to board service are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/25/2026 - 06:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JEAN CHRISTOPHE

(Last)

(First)

(Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02116

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/23/2026		M		4,712	A	⁽¹⁾	11,712	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/23/2026		M			4,712	⁽²⁾	⁽²⁾	Common Stock	4,712	$0	0	D
Stock Option (right to buy)	$107.55	06/24/2026		A		3,691		⁽³⁾	06/23/2036	Common Stock	3,691	$0	3,691	D
Restricted Stock Units	⁽¹⁾	06/24/2026		A		2,324		⁽⁴⁾	⁽⁴⁾	Common Stock	2,324	$0	2,324	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units are fully vested. The restricted stock units have no expiration date.

3. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

4. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Christophe Jean	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR